ACCELERON PHARMA INC Insider Trading for October 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC for October 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 28 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Sell | S | 35.00 | 17,872 | 625,520 | 161,031 | 178.9 K to 161 K (-9.99 %) |
| Oct 28 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Sell | S | 35.00 | 5,528 | 193,480 | 178,903 | 184.4 K to 178.9 K (-3.00 %) |
| Oct 27 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 10,000 | 38,800 | 145,751 | |
| Oct 27 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 10,000 | 38,800 | 10,000 | 0 to 10 K |
| Oct 20 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.12 | 1,000 | 29,120 | 24,500 | 25.5 K to 24.5 K (-3.92 %) |
| Oct 20 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.10 | 3,918 | 114,014 | 19,940 | 23.9 K to 19.9 K (-16.42 %) |
| Oct 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 4,000 | 3,680 | 11,500 | |
| Oct 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 29.02 | 4,000 | 116,080 | 0 | 4 K to 0 (-100.00 %) |
| Oct 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 4,000 | 3,680 | 4,000 | 0 to 4 K |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 4,082 | 7,348 | 2,414 | |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.41 | 200 | 6,082 | 25,500 | 25.7 K to 25.5 K (-0.78 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.27 | 800 | 23,416 | 25,700 | 26.5 K to 25.7 K (-3.02 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.28 | 1,193 | 36,124 | 23,858 | 25.1 K to 23.9 K (-4.76 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.17 | 2,889 | 84,272 | 25,051 | 27.9 K to 25.1 K (-10.34 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 4,082 | 7,348 | 27,940 | 23.9 K to 27.9 K (+17.11 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 10,000 | 38,800 | 155,751 | |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.25 | 10,000 | 292,500 | 0 | 10 K to 0 (-100.00 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 10,000 | 38,800 | 10,000 | 0 to 10 K |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 30.20 | 10,000 | 302,000 | 116,500 | 126.5 K to 116.5 K (-7.91 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 29.22 | 10,000 | 292,200 | 126,500 | 136.5 K to 126.5 K (-7.33 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 18,500 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.28 | 3,500 | 18,480 | 21,500 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 1,500 | 8,820 | 6,500 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 30.36 | 608 | 18,459 | 29,890 | 30.5 K to 29.9 K (-1.99 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 29.57 | 3,392 | 100,301 | 30,498 | 33.9 K to 30.5 K (-10.01 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 33,890 | 29.9 K to 33.9 K (+13.38 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 30.00 | 7,000 | 210,000 | 29,890 | 36.9 K to 29.9 K (-18.98 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.28 | 3,500 | 18,480 | 36,890 | 33.4 K to 36.9 K (+10.48 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 1,500 | 8,820 | 33,390 | 31.9 K to 33.4 K (+4.70 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 5,000 | 25,400 | 13,750 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.92 | 3,125 | 2,875 | 4,687 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 1,875 | 750 | 0 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 30.28 | 900 | 27,252 | 52,656 | 53.6 K to 52.7 K (-1.68 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 29.53 | 4,100 | 121,073 | 53,556 | 57.7 K to 53.6 K (-7.11 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 5,000 | 25,400 | 57,656 | 52.7 K to 57.7 K (+9.50 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 30.27 | 800 | 24,216 | 52,656 | 53.5 K to 52.7 K (-1.50 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 29.53 | 4,200 | 124,026 | 53,456 | 57.7 K to 53.5 K (-7.28 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.92 | 3,125 | 2,875 | 57,656 | 54.5 K to 57.7 K (+5.73 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 1,875 | 750 | 54,531 | 52.7 K to 54.5 K (+3.56 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 7.12 | 3,570 | 25,418 | 8,930 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 3,430 | 18,110 | 13,707 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.01 | 7,000 | 210,070 | 0 | 7 K to 0 (-100.00 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 7.12 | 3,570 | 25,418 | 7,000 | 3.4 K to 7 K (+104.08 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 3,430 | 18,110 | 3,430 | 0 to 3.4 K |